Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Non-Current Deffered Revenue (2020)

Historic Non-Current Deffered Revenue for Ovid Therapeutics (OVID) over the last 1 years, with Q4 2020 value amounting to $10.2 million.

  • Ovid Therapeutics' Non-Current Deffered Revenue changed N/A to $10.2 million in Q4 2020 from the same period last year, while for Dec 2020 it was $10.2 million, marking a year-over-year change of. This contributed to the annual value of $10.2 million for FY2020, which is N/A changed from last year.
  • As of Q4 2020, Ovid Therapeutics' Non-Current Deffered Revenue stood at $10.2 million.
  • Ovid Therapeutics' 5-year Non-Current Deffered Revenue high stood at $10.2 million for Q4 2020, and its period low was $9.9 million during Q3 2020.